Global Heparin Market

Global Heparin Market Size, Share, Growth Analysis, By Route of Administration(Intravenous and Subcutaneous), By End Use(Outpatient and Inpatient) - Industry Forecast 2024-2031


Report ID: SQMIG35H2166 | Region: Global | Published Date: April, 2024
Pages: 219 | Tables: 59 | Figures: 76

Global Heparin Market Insights

Global Heparin Market size was valued at USD 7.48 billion in 2022 and is poised to grow from USD 7.68 billion in 2023 to USD 9.51 billion by 2031, at a CAGR of 2.7% during the forecast period (2024-2031).

The FDA authorised the M-Enoxaparin medication from Momenta Pharmaceuticals, Inc. in August 2022. Together with Sandoz, the generics division of Novartis AG, Momenta is creating M-Enoxaparin, a generic version of lovenox with better technology. Additionally, it is given for major orthopaedic procedures like hip and knee replacement. The heparin market has recently seen new growth potential due to recent developments in heparin research that aim to produce ultra-low molecular weight heparin for use in chemotherapy. Heparin is used to treat a number of diseases and disorders, such as deep vein thrombosis, pulmonary embolism, acute coronary syndrome, atrial fibrillation, cardiopulmonary bypass, and hemofiltration during heart surgery. This gadget can be used to provide hip and knee replacements as well as other significant orthopaedic surgeries. Due to underlying causes including cardiovascular illness, the incidence of venous thrombosis is rising, which propels the growth of the global market. The market is also growing as a result of the increased use of heparin in a variety of surgical operations, including orthopaedic and heart surgeries, as well as the increase in people having these procedures. But the market's growth is constrained by a number of unfavourable heparin side effects, including thrombocytopenia caused by heparin. Further limiting factors include the fact that heparin is made from animal sources, which poses serious safety and availability issues.

$5,300
BUY NOW GET FREE SAMPLE
Want to customize this report?

Our industry expert will work with you to provide you with customized data in a short amount of time.

REQUEST FREE CUSTOMIZATION

FAQs

Global Heparin Market size was valued at USD 7.48 billion in 2022 and is poised to grow from USD 7.68 billion in 2023 to USD 9.51 billion by 2031, at a CAGR of 2.7% during the forecast period (2024-2031).

Details about each competitor are included in the heparin market competitive landscape. Included data includes an overview of the company, financials, revenue generated, market potential, investments in R&D, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launches and application dominance. Only the companies' focus on the heparin industry is mentioned in the data points above. 'Pfizer Inc. (United States)', 'Sanofi S.A. (France)', 'Leo Pharma A/S (Denmark)', 'Fresenius Kabi AG (Germany)', 'Aspen Holdings (South Africa)', 'Teva Pharmaceutical Industries Ltd. (Israel)', 'Dr. Reddy's Laboratories Ltd. (India)', 'B. Braun Melsungen AG (Germany)', 'LEO Pharma A/S (Denmark)', 'Baxter International Inc. (United States)', 'Shanghai Institute of Biological Products (China)', 'Nanjing King-friend Biochemical Pharmaceutical (China)', 'Changzhou Qianhong Bio-pharma (China)', 'Opocrin S.p.A. (Italy)', 'Nantong Pharmaceutical (China)', 'Celsus Laboratories Inc. (United States)', 'Hebei Changshan Biochemical Pharmaceutical (China)', 'Bioiberica S.A.U. (Spain)', 'Dongying Tiandong Pharmaceutical (China)', 'Shenzhen Hepalink Pharmaceutical Co., Ltd. (China)', 'Pharma Action GmbH (Germany)'

The need for heparin is increasing as coagulation diseases like venous thromboembolism (VTE), which includes both deep vein thrombosis and pulmonary embolism, are becoming more common. VTE, which includes pulmonary embolism and deep vein thrombosis, kills over 1.2 million individuals every year. Additionally, VTE is the biggest cause of death in Europe, outpacing AIDS, breast and prostate cancer, as well as traffic accidents taken together. Additionally, the global market is growing as a result of an increase in hypertension instances brought on by an unhealthy lifestyle. Heart attacks and strokes, which are on the rise, will open up new commercial prospects. According to the American Heart Association's (AHA) heart disease and Stroke Statistics, atrial fibrillation has an impact on Americans total 5.3 million. The market may be significantly impacted by rising patient demand for heparin.

With the increasing use of heparin and other anticoagulant therapies, there is a growing need for effective reversal agents to counteract their anticoagulant effects in emergency situations or during surgery. Research and development efforts are underway to develop novel anticoagulant reversal agents, providing an additional growth avenue for the heparin market.

In 2022, North America dominated the market and contributed 38.97% of total revenue. The increase in cardiovascular diseases and injuries is to blame for this. In addition, rising levels of healthcare spending and rising patient awareness in this region are the other variables that contribute to the high share. According to the CDC, heart disease will be one of the leading causes of death in the United States in 2022, killing 659,000 people a year, or 1 in every 4 fatalities.

Request Free Customization

Want to customize this report? This report can be personalized according to your needs. Our analysts and industry experts will work directly with you to understand your requirements and provide you with customized data in a short amount of time. We offer $1000 worth of FREE customization at the time of purchase.

logo-images

Feedback From Our Clients

Global Heparin Market

Product ID: SQMIG35H2166

$5,300
BUY NOW GET FREE SAMPLE